Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Florence

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Acta Clinica Belgica|September 5, 2019
Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in BelgiumPatrick Soentjens, Mieke Croughs, Christoph Burm, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
The Lancet. HIV|February 29, 2024
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trialThibaut Vanbaelen, Achilleas Tsoumanis, Eric Florence, et al.
The Lancet. HIV|April 1, 2021
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trialAndrés Esteban-Cantos, Javier Rodríguez-Centeno, Pilar Barruz, et al.
The Journal of Infectious Diseases|June 21, 2019
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment TrialChristina Ekenberg, Man-Hung Tang, Adrian G Zucco, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
AIDS (London, England)|February 10, 2018
No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell countsEdwina J Wright, Birgit Grund, Kevin R Robertson, et al.
Nature Medicine|August 12, 2022
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in BelgiumIrith De Baetselier, Christophe Van Dijck, Chris Kenyon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Acta Clinica Belgica|September 5, 2019
Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in BelgiumPatrick Soentjens, Mieke Croughs, Christoph Burm, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
The Lancet. HIV|February 29, 2024
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trialThibaut Vanbaelen, Achilleas Tsoumanis, Eric Florence, et al.
The Lancet. HIV|April 1, 2021
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trialAndrés Esteban-Cantos, Javier Rodríguez-Centeno, Pilar Barruz, et al.
The Journal of Infectious Diseases|June 21, 2019
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment TrialChristina Ekenberg, Man-Hung Tang, Adrian G Zucco, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
AIDS (London, England)|February 10, 2018
No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell countsEdwina J Wright, Birgit Grund, Kevin R Robertson, et al.
Nature Medicine|August 12, 2022
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in BelgiumIrith De Baetselier, Christophe Van Dijck, Chris Kenyon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
Pageof 12